Literature DB >> 1916095

Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine.

R A Dean1, C D Christian, R H Sample, W F Bosron.   

Abstract

A new, pharmacologically active metabolite of cocaine, ethylcocaine, has been reported in individuals after concurrent use of cocaine and ethanol. Formation of ethylcocaine may contribute to the common coabuse of these two drugs and the apparent danger of this practice. We have identified a nonspecific carboxyl-esterase that catalyzes the ethyl transesterification of cocaine to ethylcocaine in the presence of ethanol. In the absence of ethanol, this human liver esterase catalyzes the hydrolysis of cocaine to benzoylecgonine, a metabolite that is inactive as a psychomotor stimulant. A second human liver esterase is also described. This enzyme catalyzes hydrolysis of cocaine to ecgonine methyl ester, also inactive as a stimulant. These two liver esterases may play important roles in regulating the metabolic inactivation of cocaine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916095     DOI: 10.1096/fasebj.5.12.1916095

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  22 in total

1.  Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population.

Authors:  Susumu Saito; Aritoshi Iida; Akihiro Sekine; Saori Kawauchi; Shoko Higuchi; Chie Ogawa; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2003-04-29       Impact factor: 3.172

2.  The ability of bacterial cocaine esterase to hydrolyze cocaine metabolites and their simultaneous quantification using high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Remy L Brim; Kathleen R Noon; Gregory T Collins; Joseph Nichols; Diwahar Narasimhan; Roger K Sunahara; James H Woods
Journal:  Mol Pharmacol       Date:  2011-09-01       Impact factor: 4.436

3.  The persistence of illicit drug smoke residues and their recovery from common household surfaces.

Authors:  Julie L Bitter
Journal:  Drug Test Anal       Date:  2016-06-22       Impact factor: 3.345

4.  The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocaethylene in mice.

Authors:  Hanna N Wetzel; Michael R Tabet; William J Ball; Andrew B Norman
Journal:  Int Immunopharmacol       Date:  2014-12       Impact factor: 4.932

5.  Ethanol consumption reduces the adverse consequences of self-administered intravenous cocaine in rats.

Authors:  L A Knackstedt; A Ettenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-08-25       Impact factor: 4.530

6.  Conversion and pharmacokinetics profiles of a novel pro-drug of 3-n-butylphthalide, potassium 2-(1-hydroxypentyl)-benzoate, in rats and dogs.

Authors:  Jiang Li; Shao-Feng Xu; Ying Peng; Nan Feng; Ling Wang; Xiao-Liang Wang
Journal:  Acta Pharmacol Sin       Date:  2017-09-14       Impact factor: 6.150

7.  The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions.

Authors:  Robert B Parker; S Casey Laizure
Journal:  Drug Metab Dispos       Date:  2009-11-17       Impact factor: 3.922

8.  Differences in bioavailability between cocaine and cocaethylene and their implications for drug-reward studies.

Authors:  J B Nobiletti; P I Jatlow; C W Bradberry
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

9.  Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.

Authors:  Zhe-Yi Hu; Andrea N Edginton; S Casey Laizure; Robert B Parker
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

10.  Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel.

Authors:  Zhixia Qiu; Ning Li; Ling Song; Yang Lu; Jing Jing; Harendra S Parekha; Wenchao Gao; Fengjie Tian; Xin Wang; Shuangxia Ren; Xijing Chen
Journal:  Pharm Res       Date:  2013-09-14       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.